Big Historical Cash Flow
| PRM Stock | CAD 13.30 0.18 1.37% |
Analysis of Big Pharma cash flow over time is an excellent tool to project Big Pharma Split future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Dividends Paid of 1.5 M or Capital Expenditures of 3.15 as it is a great indicator of Big Pharma ability to facilitate future growth, repay debt on time or pay out dividends.
Big |
About Big Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Big balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Big's non-liquid assets can be easily converted into cash.
Big Pharma Cash Flow Chart
Add Fundamental
Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Big Pharma's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Big Pharma Split current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Big Pharma Split. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Big Pharma's Free Cash Flow is very stable compared to the past year. As of the 1st of December 2024, Change In Working Capital is likely to grow to about 10.1 K, though Change In Cash is likely to grow to (584.3 K).
Big Pharma cash flow statement Correlations
Click cells to compare fundamentals
Big Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Big Pharma cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 119.0K | (305.1K) | 1.2M | (610.6K) | (615.0K) | (584.3K) | |
| Free Cash Flow | 8.7M | 4.3M | (9.0M) | 1.1M | 11.9M | 12.5M | |
| Change In Working Capital | (3.0K) | (31.7K) | (154.3K) | 175.4K | 9.7K | 10.1K | |
| Begin Period Cash Flow | 417.1K | 536.1K | 231.0K | 1.4M | 819.2K | 829.5K | |
| Other Cashflows From Financing Activities | (6.3M) | (3.0M) | 11.5M | 962.3K | (10.5M) | (10.0M) | |
| Other Non Cash Items | 6.1M | 4.6M | (13.1M) | (1.4M) | 12.5M | 13.1M | |
| Dividends Paid | 1.5M | 1.2M | 2.2M | 1.9M | 2.1M | 1.5M | |
| Total Cash From Operating Activities | 8.7M | 4.3M | (9.0M) | 1.1M | 11.9M | 12.5M | |
| Change To Operating Activities | (54.0K) | (3.0K) | (31.7K) | (154.3K) | (138.9K) | (131.9K) | |
| Net Income | 2.6M | (217.4K) | 4.2M | 2.4M | (645.4K) | (613.1K) | |
| Total Cash From Financing Activities | (8.6M) | (4.7M) | 10.2M | (1.7M) | (12.5M) | (11.8M) | |
| End Period Cash Flow | 536.1K | 231.0K | 1.4M | 819.2K | 204.2K | 194.0K | |
| Change To Netincome | (780.2K) | 6.1M | 4.6M | (13.1M) | (15.0M) | (15.8M) |
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Big Stock
Moving against Big Stock
The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
The Cash Flow Statement is a financial statement that shows how changes in Big balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Big's non-liquid assets can be easily converted into cash.